Mostrar el registro sencillo del ítem

dc.contributor.authorMatamala, Nerea 
dc.contributor.authorLara, Beatriz
dc.contributor.authorGomez-Mariano, Gema Maria 
dc.contributor.authorMartinez Rodríguez, Selene 
dc.contributor.authorVázquez-Domínguez, Irene
dc.contributor.authorOtero-Sobrino, Álvaro
dc.contributor.authorMuñoz-Callejas, Antonio
dc.contributor.authorSánchez, Elena
dc.contributor.authorEsquinas, Cristina
dc.contributor.authorBustamante, Ana
dc.contributor.authorCadenas, Sergio
dc.contributor.authorCuri, Sergio
dc.contributor.authorLázaro, Lourdes
dc.contributor.authorMartínez, María Teresa
dc.contributor.authorRodríguez, Esther
dc.contributor.authorMiravitlles, Marc
dc.contributor.authorTorres-Duran, María
dc.contributor.authorHerrero, Inés
dc.contributor.authorMichel, Francisco Javier
dc.contributor.authorCastillo, Silvia
dc.contributor.authorHernández-Pérez, José Mª
dc.contributor.authorBlanco, Ignacio
dc.contributor.authorCasas, Francisco
dc.contributor.authorMartinez-Delgado, Beatriz 
dc.date.accessioned2024-01-23T14:24:06Z
dc.date.available2024-01-23T14:24:06Z
dc.date.issued2021-07
dc.identifier.citationArch Bronconeumol. 2021 Jul;57(7):457-463.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/17267
dc.description.abstractIntroduction: Alpha-1 antitrypsin deficiency (AATD) is a genetic condition resulting in lung and liver disease with a great clinical variability. MicroRNAs have been identified as disease modifiers; therefore miRNA deregulation could play an important role in disease heterogeneity. Members of miR-320 family are involved in regulating of multiple processes including inflammation, and have potential specific binding sites in the 3'UTR region of SERPINA1 gene. In this study we explore the involvement of miR-320c, a member of this family, in this disease. Methods: Firstly in vitro studies were carried out to demonstrate regulation of SERPINA1 gene by miR-320. Furthermore, the expression of miR-320c was analyzed in the blood of 98 individuals with different AAT serum levels by using quantitative PCR and expression was correlated to clinical parameters of the patients. Finally, HL60 cells were used to analyze induction of miR-320c in inflammatory conditions. Results: Overexpression of miR-320 members in human HepG2 cells led to inhibition of SERPINA1 expression. Analysis of miR-320c expression in patient's samples revealed significantly increased expression of miR-320c in individuals with pulmonary disease. Additionally, HL60 cells treated with the pro-inflammatory factor lipopolysaccharide (LPS) showed increase in miR-320c expression, suggesting that miR-320c responds to inflammation. Conclusion: Our findings demonstrate that miR-320c inhibits SERPINA1 expression in a hepatic cell line and its levels in blood are associated with lung disease in a cohort of patients with different AAT serum levels. These results suggest that miR-320c can play a role in AAT regulation and could be a biomarker of inflammatory processes in pulmonary diseases.es_ES
dc.description.sponsorshipThis study was financed by grants from the Institute of Health Carlos III (AESI PI14CIII/00070 and PI17CIII/00042) and SEPAR (Sociedad Española de Neumología y Cirugía Torácica), project 92/2014.es_ES
dc.language.isoenges_ES
dc.publisherSociedad Española de Patología Respiratoriaes_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectmicroRNAes_ES
dc.subjectmiR-320ces_ES
dc.subjectAlpha-1 antitrypsin deficiencyes_ES
dc.subjectLung diseasees_ES
dc.subjectInflammationes_ES
dc.subject.meshLung Diseases es_ES
dc.subject.meshMicroRNAs es_ES
dc.subject.meshalpha 1-Antitrypsin es_ES
dc.subject.meshalpha 1-Antitrypsin Deficiency es_ES
dc.subject.mesh3' Untranslated Regions es_ES
dc.subject.meshHumans es_ES
dc.subject.meshInflammation es_ES
dc.subject.meshLung es_ES
dc.titlemiR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Diseasees_ES
dc.typeresearch articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID35698951es_ES
dc.format.volume57es_ES
dc.format.number7es_ES
dc.format.page457-463es_ES
dc.identifier.doi10.1016/j.arbr.2020.03.031es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.contributor.funderSociedad Española de Neumología y Cirugía Torácica es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1579-2129es_ES
dc.relation.publisherversionhttps://doi.org/10.1016/j.arbr.2020.03.031es_ES
dc.identifier.journalArchivos de bronconeumologiaes_ES
dc.repisalud.centroISCIII::Instituto de Investigación de Enfermedades Rarases_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/null/null/ISCIII Subprograma de proyectos de investigacion en salud . Modalidad proyectos en salud. (2014)/PI14CIII/00070es_ES
dc.relation.projectFISinfo:fis/Instituto de Salud Carlos III/Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia/Subprograma Estatal de Generación de Conocimiento/PI17-ISCIII Modalidad Proyectos de Investigacion en Salud Intramurales. (2017)/PI17CIII/00042es_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional